Biostate AI, a leader in AI-driven molecular diagnostics, has announced a landmark collaboration with Narayana Health, one of the world’s largest cardiac care networks, through its Indian subsidiary Bayosthiti AI. The partnership aims to create the world’s largest India-specific cardiac AI dataset by analyzing molecular data from 12,000 patients at the Narayana Institute of Cardiac Sciences in Bengaluru. This initiative addresses a critical gap in global healthcare: the lack of cardiovascular risk tools calibrated for South Asian populations, who develop heart disease up to 10 years earlier than Western patients and often face higher mortality due to late or missed diagnoses. The study leverages Biostate AI’s proprietary BIRT™ (Barcode-Integrated Reverse Transcription) technology, which enables cost-effective, high-throughput sequencing of complete RNA profiles—the real-time molecular instructions cells follow. By analyzing these dynamic biological signals, the AI models can detect early signs of heart disease months or even years before structural damage appears on traditional imaging or blood tests. This approach marks a shift from reactive intervention to proactive prevention. Unlike conventional methods that identify disease after it has caused physical changes, RNA sequencing captures the biological shift toward disease. Biostate AI’s generative AI models learn from millions of RNA expressions, identifying high-risk individuals up to two to three years earlier than current standards, with diagnostic accuracy matching invasive procedures. The collaboration brings together three essential elements: cutting-edge molecular technology, access to a vast clinical population, and real-world validation. Narayana Health’s annual volume of over 60,000 cardiac procedures provides both the data and infrastructure needed to train and validate AI models against actual patient outcomes. Dr. David Zhang, CEO of Biostate AI, emphasized the strategic importance of building precision medicine tools for India first. “By developing solutions tailored to the Indian population, we’re not just entering a market—we’re helping define the future of global healthcare,” he said. Dr. P.M. Uthappa, Group Chief Medical Director at Narayana Health, highlighted the clinical transformation potential. “This isn’t the future of medicine—it’s the present. The ability to predict heart attacks before they happen is a game-changer for patient care.” Kutapa Muthanna, CEO of Bayosthiti AI, noted that the project is about more than closing a data gap—it’s about building a new model of healthcare. “This is precision medicine created by Indians, for Indians. And it has the potential to scale across South Asia and beyond.” The three-phase study will allow for continuous model refinement and validation. If successful, the findings could lead to a scalable, blood-based diagnostic test for early heart disease detection, deployable across India’s diverse healthcare system and eventually in other underserved regions. The partnership underscores Biostate AI’s mission to make precision medicine accessible at population scale. With Bayosthiti AI now established as India’s first AI-first healthcare company, the collaboration represents a major step toward Lifetime Health Management powered by 24/7 AI Clinical Assistants and AI-driven research. As the world moves toward personalized medicine, this initiative demonstrates how combining deep molecular insights, clinical scale, and artificial intelligence can create equitable, forward-looking healthcare solutions—starting in India, with global impact.